Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion

Novel adjuvant strategies are needed to optimize outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC). The adjuvant treatment of ROS Proto-Oncogene 1 (ROS1) fusion-positive resected NSCLC is challenging because there is no curative confirmed rand...

Full description

Bibliographic Details
Main Authors: An-guo Chen, Dong-sheng Chen, Si Li, Le-le Zhao, Ming-zhe Xiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
ROS1 fusion
crizotinib
adjuvant treatment
NSCLC
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.837219/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.837219/full

Similar Items